This chapter underscores the pivotal role of immune receptors, particularly Toll-like receptors (TLRs) and NOD-like receptors (NLRs), in the intricate interplay between metabolic diseases and their associated cardiovascular comorbidities. Their involvement extends beyond mere initiation, profoundly influencing the progression of these complex conditions. The recognition of TLRs and NLRs as promising therapeutic targets is a significant advancement, offering potential avenues for intervention in both metabolic disorders and their cardiovascular sequels. The significance of these pattern recognition receptors (PRRs) lies in their capacity to orchestrate inflammatory responses, a critical factor in the pathogenesis of metabolic diseases. Dysregulation of these pathways contributes to chronic, low-grade inflammation, a hallmark of conditions such as obesity and type 2 diabetes. This persistent inflammation, in turn, fuels the development of cardiovascular complications such as atherosclerosis, hypertension, and heart failure. Targeting TLRs and NLRs presents a strategic approach to modulate these inflammatory cascades. By selectively inhibiting or modulating the activity of these receptors, it may be possible to mitigate the detrimental effects of chronic inflammation and prevent or delay the onset of associated comorbidities. However, this approach requires a thorough understanding of the specific TLR and NLR subtypes involved in various disease processes, as well as the intricate signaling pathways they activate. Furthermore, the development of therapeutic strategies targeting PRRs must consider the potential for off-target effects and the need for personalized medicine. Given the diverse expression patterns and functional roles of TLRs and NLRs across various cell types and tissues, a tailored approach is essential to maximize efficacy and minimize adverse effects. Consequently, ongoing research is focused on identifying specific ligands and inhibitors that can selectively target these receptors, paving the way for novel therapeutic interventions.